Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC)

被引:24
|
作者
Kim, Seong-Jang [1 ,5 ]
Kim, Yong-Ki [2 ]
Kim, In Joo [5 ]
Kim, Young Dae [3 ,5 ]
Lee, Min Ki [4 ,5 ]
机构
[1] Pusan Natl Univ, Dept Nucl Med, Sch Med, Pusan 602739, South Korea
[2] Private Clin Endocrinol & Metab & Nucl Med, Pusan, South Korea
[3] Pusan Natl Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Pusan 602739, South Korea
[4] Pusan Natl Univ, Sch Med, Dept Internal Med, Pusan 602739, South Korea
[5] Pusan Natl Univ, Sch Med, Med Res Inst, Pusan 602739, South Korea
关键词
Dual time point; F-18; FDG; Non-small cell lung cancer; Overall survival; Disease-free survival; POSITRON-EMISSION-TOMOGRAPHY; PANCREATIC-CANCER; NECK-CANCER; RADIOTHERAPY; RECURRENCE; SURVIVAL; HEAD; CT;
D O I
10.1016/j.radonc.2010.11.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of the current study was to investigate the prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) NSCLC. Methods: A retrospective review identified 66 patients with surgically resected early (stage I & II) NSCLC who received dual time point F-18 FOG PET/CT at diagnosis of cancer. Survival analysis was conducted using Kaplan-Meier analysis, and survival curves stratified by age, sex, mediastinal lymph node involvement, TNM staging, SUVmaxE, SUVmaxD, and %Delta SUVmax were generated for estimation of overall survival and disease-free survival (DFS). Independent predictive factors for survival were determined using Cox proportional hazard model. Results: The overall survival and DFS were better in patients with tumor SUVmaxE <= 5.75 than the patients with tumor SUVmaxE >= 5.75. Seventeen patients (18.2%) with a tumor SUVmaxD >= 6.8 and 4 of 33 patients with tumor SUVmaxD <= 6.8 recurred during follow-up period. The median disease-free survival of the patients with tumor SUVmaxD >= 6.8 was 31.7 months and was significantly worse than the patients with tumor SUVmaxD <= 6.8 (Log rank test, X-2 = 10.45, p = 0.0012). The %Delta SUVmax did not have prognostic values for overall survival and disease-free survival. The SUVmaxE and SUVmaxD were the potent predictors for overall survival. Also, the potent predictor of DFS was the SUVmaxE. Conclusion: In conclusion, %Delta SUVmax measured by dual time point F-18 FDG PET/CT might not have a prognostic value for overall survival and DFS in surgically resected early stage (stage I & II) NSCLC. (C) 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 98 (2011) 105-108
引用
收藏
页码:105 / 108
页数:4
相关论文
共 50 条
  • [1] Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC)
    Kim, Seong-Jang
    Kim, Yong-Ki
    Kim, In-joo
    Pak, Kyoungjune
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [2] Prognostic role of baseline 18F-FDG pet/CT in stage I and stage ii non-small cell lung cancer
    Dondi, Francesco
    Albano, Domenico
    Bellini, Pietro
    Cerudelli, Elisabetta
    Treglia, Giorgio
    Bertagna, Francesco
    CLINICAL IMAGING, 2023, 94 (71-78) : 71 - 78
  • [3] Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer
    Kim, Y. S.
    Kim, S. J.
    Kim, Y. K.
    Kim, I. J.
    Kim, Y. D.
    Lee, M. K.
    NEOPLASMA, 2011, 58 (03) : 245 - 250
  • [4] Prognostic stratification using F-18 FDG PET/CT in patients with advanced stage (Stage III and IV) non-small cell lung cancer
    Kim, Y. S.
    Lee, M. K.
    Kim, S. J.
    Kim, I. J.
    Kim, Y. K.
    Jo, W. S.
    Park, S. K.
    NEOPLASMA, 2010, 57 (03) : 241 - 246
  • [5] Stage IIIb or IV NSCLC lung cancer on CT, what is the point of a F-18 FDG PET/CT?
    Birchall, J. D.
    McCulloch, G.
    Mhlanga, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S293 - S293
  • [6] STAGE IIIB OR IV NSCLC LUNG CANCER ON CT, WHAT IS THE POINT OF F-18 FDG PET/CT?
    Birchall, J.
    Kumar, M.
    McCulloch, G.
    RADIOTHERAPY AND ONCOLOGY, 2010, 94 : S32 - S32
  • [7] Predictive value of SUVmax measured by 18F-FDG PET/CT in patients with early stage non-small cell lung cancer
    Qiang, Guangliang
    Xu, Rui
    Yan, Jue
    Yu, Qiduo
    Xiao, Fei
    Song, Zhiyi
    Tian, Yanchu
    Shi, Bin
    Liang, Chaoyang
    Guo, Yongqing
    Liu, Deruo
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 3353 - 3361
  • [8] Prognostic role of baseline 18F-FDG PET/CT in stage I and II non small cell lung cancer
    Dondi, F.
    Albano, D.
    Bertoli, M.
    Bellini, P.
    Calabro, A.
    Gregorelli, M.
    Talin, A.
    Ferrarini, G.
    Franzoni, G.
    Bertagna, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S381 - S381
  • [9] Prognostic Value Of Dual-time Point (18)F-FDG PET Examination In Patients With Stage I Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy
    Onishi, H.
    Sato, Y.
    Nambu, A.
    Kuriyama, K.
    Komiyama, T.
    Marino, K.
    Araya, M.
    Sano, N.
    Araki, T.
    Sawada, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S586 - S586
  • [10] Dual-Time-Point F-18 FDG PET/CT for Evaluation of Intrathoracic Lymph Nodes in Patients With Non-Small Cell Lung Cancer
    Shinya, Takayoshi
    Rai, Kammei
    Okumura, Yoshihiro
    Fujiwara, Keiichi
    Matsuo, Kiyoshi
    Yonei, Toshiro
    Sato, Toshio
    Watanabe, Kazuhiko
    Kawai, Haruyuki
    Sato, Shuhei
    Kanazawa, Susumu
    CLINICAL NUCLEAR MEDICINE, 2009, 34 (04) : 216 - 221